Apremilast and Adalimumab in Psoriatic Arthritis Patients

Conditions: Psoriatic Arthritis, Ultrasound Assessment, TNF

Sex: All

Ages: 18 Years – 70 Years

Healthy volunteers: No

Phase: NA

Enrollment: 60

Sponsor: Tanta University

Location: Tanta University Tanta

Summary

The aim of this work is to compare the efficacy of Apremilast combined with Methotrexate versus Adalimumab combined with Methotrexate

Eligibility Criteria

Inclusion Criteria: * This study will include 60 adult Psoriatic arthritis patients \>18 years old, fulfilling the (CASPAR) classification criteria of Psoriatic arthritis and have an inadequate response to methotrexate therapy for at least 3 months. * Psoriatic arthritis patients with peripheral musculoskeletal domains (peripheral arthritis, dactylitis and enthesitis) as well as skin and nail domains Exclusion Criteria: * Patients who received previous biologic agents or Janus kinase inhibitors. * Patients with axial and ocular involvement. * Current or recent serious infection including tuberculosis or hepatitis B/C . * Current or past history of malignancy (within five year). * Pregnant or breastfeeding women or women planning pregnancy during the study period . * Severe uncontrolled comorbidities such as heart failure, severe liver disease, or chronic kidney disease (eGFR \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07398651). StuddyBuddy aggregates publicly available trial information.